NCT02794961

CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies

Application of Humanized Anti-CD22 Antibody in CAR-T Therapy of B Cell Hematological Malignancies

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Kai Lin Xu; Jun Nian Zheng · Academic / Other
• Sex: All
• Age: 4 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

CD19 expression on B cell frequently lost after CD19-targeting CAR-T therapy. In present study, we construct a CD22-targeting chimeric antigen receptor to overcome this issue.

Detailed description

CD19 is an ideal target with great potential for treating B-cell-derived hematological malignancies. Although the complete remission rate is as high as 93% by using CD19-targeting CAR-T technology, approximately 60% patients will have recurrent disease. Among all the recurrent patients, two thirds is revealed to loss their CD19 expression on B cell surface. For overcoming this issue, we establish a new chimeric antigen receptor containing humanized single chain antibody sequence to target CD22 molecule on B cells.

Conditions

• Recurrent or Refractory B Cell Malignancy

Interventions

Type	Name	Description
BIOLOGICAL	CD22 CAR-T	Autologous CAR-T cells with average 1\*10\^6 cells/kg body weight

Timeline

• Start date: 2016-06-01
• Primary completion: 2018-06-01
• Completion: 2019-06-01
• First posted: 2016-06-09
• Last updated: 2016-06-09

Locations

1 site across 1 country: China